{"name":"Taiho Oncology, Inc.","slug":"taiho-oncology-inc","ticker":"","exchange":"","domain":"taihooncology.com","description":"","hq":"Princeton","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2015-01-01","label":"Lonsurf first approved","drug":"Lonsurf","drugSlug":"tipiracil","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"ASTX727","genericName":"ASTX727","slug":"astx727","indication":"Myelodysplastic syndrome (MDS), including MDS with excess blasts","status":"phase_3"},{"name":"ASTX727 LD","genericName":"ASTX727 LD","slug":"astx727-ld","indication":"Other","status":"phase_1"},{"name":"ASTX727 SD","genericName":"ASTX727 SD","slug":"astx727-sd","indication":"Other","status":"phase_1"},{"name":"CPT-11","genericName":"CPT-11","slug":"cpt-11","indication":"Other","status":"marketed"},{"name":"Tolinapant","genericName":"Tolinapant","slug":"tolinapant","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"TAS-120","genericName":"TAS-120","slug":"tas-120","indication":"Cholangiocarcinoma with FGFR2 fusion or rearrangement","status":"phase_3"},{"name":"TAS6417","genericName":"TAS6417","slug":"tas6417","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors, Phase 3 development)","status":"phase_3"},{"name":"Lonsurf","genericName":"TIPIRACIL","slug":"tipiracil","indication":"Malignant tumor of colon","status":"marketed"}]}],"pipeline":[{"name":"TAS-120","genericName":"TAS-120","slug":"tas-120","phase":"phase_3","mechanism":"TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth.","indications":["Cholangiocarcinoma with FGFR2 fusion or rearrangement","Other FGFR-altered solid tumors"],"catalyst":""},{"name":"TAS6417","genericName":"TAS6417","slug":"tas6417","phase":"phase_3","mechanism":"TAS6417 is a small-molecule inhibitor of TGF-β signaling that blocks the TGF-β receptor pathway to reduce immunosuppression in the tumor microenvironment.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors, Phase 3 development)"],"catalyst":""},{"name":"ASTX727","genericName":"ASTX727","slug":"astx727","phase":"phase_3","mechanism":"ASTX727 is a fixed-dose combination of decitabine and cedazuridine that inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes in myelodysplastic syndrome.","indications":["Myelodysplastic syndrome (MDS), including MDS with excess blasts"],"catalyst":""},{"name":"ASTX727 LD","genericName":"ASTX727 LD","slug":"astx727-ld","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASTX727 SD","genericName":"ASTX727 SD","slug":"astx727-sd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CPT-11","genericName":"CPT-11","slug":"cpt-11","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lonsurf","genericName":"TIPIRACIL","slug":"tipiracil","phase":"marketed","mechanism":"Lonsurf works by inhibiting the enzyme thymidine phosphorylase, which is involved in the breakdown of certain cancer medications.","indications":["Malignant tumor of colon","Malignant tumor of stomach"],"catalyst":""},{"name":"Tolinapant","genericName":"Tolinapant","slug":"tolinapant","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNEpiODQ0MkZNRlo0UFVBcTQ2a0dPTllwbjZtS0tuekRCNkMtMjdWX1haNkFUSnBfTzBrMlpHbGRXU2w0cUsxT3h1ck5hZGM4WjZnWTBvTGlNdmZFSjBfQ216bl94V19wY09RRjJGYWZ4VGtSTFIzWkxuSC16X0plSXhjUk1BUHVXX0F0R3FZVERNd3otUWlRSERxNW5GYmRiOURoNElJR2NETUJmeDNYUTBvOXBfUUtOT3lEdndac3hlem0wTkZjcEh2QTQ5dzBSbEI3dElFQ1pBOHFvem5jU2Mxcw?oc=5","date":"2026-02-19","type":"deal","source":"PRWeb","summary":"Demeetra Announces Renewal of Research License for piggyBac® Technology with Taiho Pharmaceutical Co., Ltd. - PRWeb","headline":"Demeetra Announces Renewal of Research License for piggyBac® Technology with Taiho Pharmaceutical Co., Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPV2xKMWVXUUdLM3VGOWdRYXpvcUlKa2hiV2JNVkFicWpXN2pOd1V1TURfYzNnTXNqTXA0Z05sdUp0dmo5X09YQUhQQTdaN01sQUxNcXdndzVxekhWbFhYSzdITFNRVUNzb1RNczBadVB5YlZoRGN3MUJQcU1mOVpTZHg5ZUIyX25Cb2hfelVkcWVFdEhJM1ZMd1d3ejhXNTV5OUZLX2E3NjF2bXUxLTN2bDdjbFJJRERU?oc=5","date":"2026-01-29","type":"pipeline","source":"ROI-NJ","summary":"Taiho Oncology names Melnyk president and CEO, succeeds retiring Whitten - ROI-NJ","headline":"Taiho Oncology names Melnyk president and CEO, succeeds retiring Whitten - ROI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPRXNIVFZCd0pKb1RVN1Y5c0tTQ211enh0MXc3MHVSZTFsZUFxdVJJVVM4N0h6Rk82NXowTzBZSnh5VU45ZjBucEFPUk5Xd3VVaVBOdHFXcEliNzNIcE9MQjJIMDVsV1owZkFkY3kzMkhRVmxjQlE3a3F3dTVVS1drVU9kYW1iSjdFTjZQeGJwbDZJWEczX2N6VE9adERYWkpycUZ0eFUtTl9jdlMyeEt5anY1bkdYSEpQd0praHVJcFVvam5tMW5Temd3?oc=5","date":"2026-01-28","type":"pipeline","source":"businesswire.com","summary":"Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer - businesswire.com","headline":"Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOLUVmOW55bnpmQklmaU1uZXdhSE14UE1IdFNJZVhhakZyYXBqSmJ2VWdwejRFNThnSnFFTnM4VFVid0JfUlVMeHJhVUN6R2ZRUXphamZKWGtHcmtZeHJSZ0RYZnRWWHp6VFpTM25kNGpfLVg3UDVRMmxaSXJKSHNTTk8xWmhxQVBhZEF3T2JhLWdvQnpiSjhrUGY3S0tMaXBIS2hXaHFlUmtsWExSS0l3THM5ejVWVV80bU1XTE1JcWVRMVFrS3c?oc=5","date":"2026-01-20","type":"pipeline","source":"businesswire.com","summary":"Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer - businesswire.com","headline":"Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxPTFQ0ckpnOVFyR2J6Q2RTWTZVcUhsSWVIcUpKeUhGV0lfbkV5OGtjY0xlZ3B1TVl6TW5uWURfYldZLWg2SFRnc19QcmFQcTBRYWVvSWxUY0RicTVIM09kdERScmhhRkNzNGJ6ZmlHTU9RSnFmMVU1c0tzaUh3dWs3cUZvMDl6aUVXRDB4M3JBQkxxV2daWFA3V3lzS29pLU1NaHZISGxNLWFQTjd4Qm14Wl8teVJWTEdrZjlRYTlMR3lJWDVYOFpHS3RiQzMtODJJcjNCT2FVTzdSLV82RkFQQ2FVMTlUTzI0anlnYURTQm1WaVlodzZxcmcyeEJ3cXdXNWNrMDlyb2ZqYl9Xek1QTk1wUEMyUnFFZDhsZ0gyZkYtcDQ4VGlNSWpnSEEtM0F4T2J3UjhKZERnOTM2U3hQNE5mRXN0azI1SzgyRzNkX05fdUR4aGo1c0hNQQ?oc=5","date":"2025-12-08","type":"regulatory","source":"PR Newswire","summary":"Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition - PR Newswire","headline":"Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-20","type":"pipeline","source":"PR Newswire","summary":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanc","headline":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQZGdtS2g1cmF5aWJwb1J1emNMVmdaRmlRNFBnNEpBRjVNLW96NjNhSUJGN3FOZHFfRGpwd2pCRTQyRW45ZV90aTZkVFQtSnprekJrM2NlWjZmNFpYNGVsOHRjdDNTWm05NTJySnBRNlQ0bnE1OWNudUZkM3dzVHpKYU8wSmRONDRqc3VuejI1TFJXUk04aUs0Ym9yQWIyNUZVVW1vLVRTWnJiVkNVNEVYVXFocWRrNWtlWHM2QlhlYnVlZHRpRkV5TkNwY3hZeEdieldkVHVPc3MwM1ZxV0RQaV8wNXpZajRDYW5JZXNOU3ZQMU5POHNYZzdkNWNEU0RRWXp5LUFJdmxMX0MxXzRBekMwdjN4bkZKZUhreWtlUk93YmVYSTdwaGcwazB0NnhXc1djYzcwOE1GUEdJNWZxVFV5OEk?oc=5","date":"2025-10-12","type":"trial","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Act","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPRjBNSGlSTG1MN1FSRlNpS2I2OEM2MElJRDlLZEc5MFZvcUxUZXJvd2ZRRWhkdktFci1XTmw4UU4tVENzc3pkUVpuQTRzQ3FTaEN0RkNmbnNCMzg0UWlQRWpQY1k2RnUyLWNwb1VvLVNmRk5scC0zTElEUGVFR0dyT0t6NWkzMW5vNzF1MVJfQWZNRjExdWhSUmtVUVlxUnNwNV9HdHVuX3RPTUNBVE9tQmdzeEotX256M24xOWx1WHJBMWFqbTBCU09kTENQREtaMzRINmNCWlRJMExlNV9rNE1HOGpoR1pERnA3SnllNXRLeHNSZmpackZPSFlaMnVkeUFFY1Zn?oc=5","date":"2025-09-09","type":"trial","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPMWpxWWJfWXhiRVh5dnJ0eS1hSHZNOTlsMWdVU0Z4MkpWU2xmRlp2bFpZUXRtMGN3aF9zdG1GQkdPb0Vzc2ZKZi05aHpXSmJMM3kyNGx5LVJyeU41ekRfSjU2MF9jd3IxS29QVXZJa0xpMDFMQzNQLWxlYTNKWGMzQ1I3ejA3N1FqNGFIdk5qb2JiRmF2c3FoemQ4azVvNGNSMnlpTVBQRXc2a1g5WHNsWU1ZMGZSamFzTzRzNDFJTi1KVVJzc3UwakdfRGNQOW85dkpVZ2JOTjJlLXlSUEc0?oc=5","date":"2025-07-25","type":"pipeline","source":"PR Newswire","summary":"Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025 - PR Newswire","headline":"Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNaEhEb1Q0X1p1c2pXUXpoVXBWRW40YnRKOTRZbGlneVZyN1ZwUW5sZWNBaUh3TEtsUUZOdkpYV2hGTnpvYW1YWkJkUy1YNm1yRGdPLTNnRHFPTy1HTF9Od01ybGlxMGp1RG5WMUdXeUc1aGl5T3REcjJncW1RZERGWmJVbHZxemNNdzE5Zms4QnRVRk44ckJJT3loUXJ6VV9la3Ftc1lPYW1rUHF6aXVZbWRuZnU1NXZYNW12ZlZqalpLbjdnT1hyTDFERXdXN1g1RFM5bmQ1NGNIZkdFa1RkT0lVTFFLeHQ2QzVqbWRhM3NWUUhEVVZZYWEzT1NRVUVSTm1vbmhwTXktTTNoMTlnb1c5S0dSNHc5LVV1T3h6VURVZw?oc=5","date":"2025-07-22","type":"pipeline","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Confe","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-09","type":"regulatory","source":"PR Newswire","summary":"Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia - PR ","headline":"Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZW9QT003T0R6ZVlON25IMW5ndC01blB2b01hQk9GcUpZLXJoMFhTYU5DekhEVjVOb0NUR0tvTXh5bUU4TVY5SG9VUENTeFdmS2xZREdETU80SnhvMkJKS05HSnZydnhNMklucHg1c29RS3JJMXFEb3pwQU9OYUlFaWNXS25VZk1OM2NaeTFBb3hiNFo2VnJUdzhiLWJtTFdRbkNpdUkxelVQX19BVjl1NDduYWlMa0RCTXhPcHZ3?oc=5","date":"2025-02-11","type":"pipeline","source":"Stanford Graduate School of Business","summary":"Product Manager Leads Global Team Developing New Cancer Drug - Stanford Graduate School of Business","headline":"Product Manager Leads Global Team Developing New Cancer Drug","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":3,"phase_1":3,"marketed":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}